
|Articles|November 30, 2021
Building Biotech Series with Sue Fletcher
Author(s)Thermo Fisher Scientific
When university and industry researchers work in tandem to conquer big challenges in medicine, they can achieve much more together than they ever could apart. Sue Fletcher, a pioneer in RNA therapeutic and Chief Scientific Officer at PYC Therapeutics, know this firsthand. She has spent decades in the field and is the co-developer of some revolutionary genetic therapies for treating rare diseases. Here, Dr. Fletcher speaks with BioPharm International about her work in this field, her incredible career, and how she’s inspiring young scientists in this complex area.
Episodes in this series

Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Trending on BioPharm International
1
Green Chemistry’s Role in Advancing US Chemical Innovation
2
Next-Generation Modalities Drive New Antibody Discovery
3
Industry Outlook 2026: Biopharma Industry Confronts Skills Shortage with Strategic Automation (Part 2)
4
GSK Acquisition of RAPT Signals Shift Toward Long-Acting Anti-IgE Therapies
5












